
Biliary Atresia - Pipeline Insight, 2025
Description
DelveInsight’s, “Biliary Atresia – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Biliary Atresia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Biliary Atresia: Overview
Biliary atresia is a blockage in the tubes (ducts) that carry bile from the liver to the gallbladder. This congenital condition occurs when the bile ducts inside or outside the liver do not develop normally. It is not known why the biliary system fails to develop normally. Typically, the first sign of biliary atresia is yellowing of the skin and whites of the eyes, called jaundice, which results from the buildup of bile in the body. Infants with biliary atresia typically develop jaundice by 3 to 6 weeks of age. Physical exam is performed to feel for an enlarged liver. Other tests include: Abdominal x-ray, Abdominal ultrasound, Blood tests to check total and direct bilirubin levels, Hepatobiliary iminodiacetic acid (HIDA) scan, also called cholescintigraphy, to help determine if the bile ducts and gallbladder are working properly, Liver biopsy to determine severity of cirrhosis or to rule out other causes of jaundice, and X-ray of the bile ducts (cholangiogram). Doctors treat biliary atresia with a surgery called the Kasai procedure and eventually, in most cases, a liver transplant. To make sure infants and children with biliary atresia get enough nutrients and calories, doctors may recommend a special eating plan and supplements.
""Biliary Atresia - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Atresia pipeline landscape is provided which includes the disease overview and Biliary Atresia treatment guidelines. The assessment part of the report embraces, in depth Biliary Atresia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Atresia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Geography Covered
- Global coverage
Biliary Atresia: Overview
Biliary atresia is a blockage in the tubes (ducts) that carry bile from the liver to the gallbladder. This congenital condition occurs when the bile ducts inside or outside the liver do not develop normally. It is not known why the biliary system fails to develop normally. Typically, the first sign of biliary atresia is yellowing of the skin and whites of the eyes, called jaundice, which results from the buildup of bile in the body. Infants with biliary atresia typically develop jaundice by 3 to 6 weeks of age. Physical exam is performed to feel for an enlarged liver. Other tests include: Abdominal x-ray, Abdominal ultrasound, Blood tests to check total and direct bilirubin levels, Hepatobiliary iminodiacetic acid (HIDA) scan, also called cholescintigraphy, to help determine if the bile ducts and gallbladder are working properly, Liver biopsy to determine severity of cirrhosis or to rule out other causes of jaundice, and X-ray of the bile ducts (cholangiogram). Doctors treat biliary atresia with a surgery called the Kasai procedure and eventually, in most cases, a liver transplant. To make sure infants and children with biliary atresia get enough nutrients and calories, doctors may recommend a special eating plan and supplements.
""Biliary Atresia - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Atresia pipeline landscape is provided which includes the disease overview and Biliary Atresia treatment guidelines. The assessment part of the report embraces, in depth Biliary Atresia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Atresia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Atresia R&D. The therapies under development are focused on novel approaches to treat/improve Biliary Atresia.
- Odevixibat: Albireo Pharma
- Major Players in Biliary Atresia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
- Biliary Atresia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- How many companies are developing Biliary Atresia drugs?
- How many Biliary Atresia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Biliary Atresia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Biliary Atresia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Biliary Atresia and their status?
- What are the key designations that have been granted to the emerging drugs?
Biliary Atresia Emerging Drugs Chapters
This segment of the Biliary Atresia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Biliary Atresia Emerging Drugs
Further product details are provided in the report……..
Biliary Atresia: Therapeutic Assessment
This segment of the report provides insights about the different Biliary Atresia drugs segregated based on following parameters that define the scope of the report, such as:
Biliary Atresia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Atresia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Atresia drugs.
Biliary Atresia Report Insights
Current Treatment Scenario and Emerging Therapies:
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Biliary Atresia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Pregistration)
- Comparative Analysis
- Nefecon: Calliditas Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- BION-1301: Chinook therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- Comparative Analysis
- HR19042: Jiangsu HengRui Medicine
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Biliary Atresia Key Companies
- Biliary Atresia Key Products
- Biliary Atresia- Unmet Needs
- Biliary Atresia- Market Drivers and Barriers
- Biliary Atresia- Future Perspectives and Conclusion
- Biliary Atresia Analyst Views
- Biliary Atresia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.